Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06994338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tirzepatide for Alcohol Use Disorder

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 14, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Sep 15, 2025 to Oct 6, 2025
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints expanded, about 16 words
    • Site details revised
  2. Start date: Jun 2025 to Sep 15, 2025
    • Primary and study completion dates: Aug 2026 to Aug 31, 2026
    • Eligibility criteria revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Trial Details
NCT Number NCT06994338
Lead Sponsor University of Southern California
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions
(from sponsor)		 Alcohol Use Disorder, Obesity and Overweight, Alcohol
Related terms Alcoholism, Behavior, Addictive, Obesity, Overweight
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov